Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill Sells 3,748 Shares

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This trade represents a 7.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $20.36 on Thursday. The business’s 50-day simple moving average is $21.20 and its 200 day simple moving average is $23.12. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $17.05 and a 52-week high of $39.83. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market capitalization of $2.53 billion, a PE ratio of -4.06 and a beta of 0.91.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. increased its holdings in Arrowhead Pharmaceuticals by 9.4% during the third quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company’s stock worth $373,000 after buying an additional 1,658 shares during the last quarter. World Investment Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 700 shares during the period. Geode Capital Management LLC lifted its stake in Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after purchasing an additional 26,171 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth approximately $345,000. Finally, Wellington Management Group LLP raised its stake in Arrowhead Pharmaceuticals by 1.5% in the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock valued at $1,199,000 after buying an additional 886 shares during the period. Institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ARWR shares. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. HC Wainwright lifted their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Finally, Citigroup cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.70.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.